The collaborators will present positive preclinical data from a study of its lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), for the treatment of KRASG12C mutant non-small ...

In a world where every scroll, search, and swipe leave a data trail, the future of PR doesn’t lie in better stories, it lies in smarter ones. Over the past few years, I’ve had the opportunity to work ...

SAN DIEGO, March 20, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the long ... a highly effective long-term treatment option for individuals ...

The latest 2-year follow-up data on golidocitinib as a maintenance therapy for peripheral ... Approximately 40% of patients with complete response (CR) and 80% with partial response (PR) experience ...